Clinical Trial Detail

NCT ID NCT02485652
Title Phase II Trial of HM61713 for the Treatment of >= 2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hanmi Pharmaceutical Company Limited
Indications

lung non-small cell carcinoma

Therapies

Olmutinib

Age Groups: adult senior

No variant requirements are available.